4DMedical signs commercial contract with pharmaceutical company
Posted 9 August 2021 Respiratory imaging disruptor and BioMelbourne Network member 4DMedical today announced the signing of a commercial contract with Novartis. Under the terms of the agreement, XV Ventilation Reports will be provided to Novartis on a…
BioCurate and Monash accelerate research into treatments for breast cancer
Posted: 2 August 2021 The first award under BioCurate’s new “Proof of Concept” fund has been granted to the Monash Biomedicine Discovery Institute (BDI). This award will support the key research needed to determine the effectiveness of targeting…
Immutep completes second tranche of institutional placement
Posted: 2 August 2021 BioMelbourne Network member Immutep has completed the second tranche of its institutional placement, details of which were announced to the market on 21 June 2021. The second tranche of the Placement comprises the…
CTxONE Launches New Name, New Brand > Oncology One
Posted: 27 July 2021 Australian biotech company and BioMelbourne member, CTxONE, has announced it has re-branded to ‘Oncology One’ – a move that will support its goal to raise and deploy meaningful capital to progress small molecule cancer…
Clarivate report: achieving patient centricity at scale
Posted 23 July 2021 Patient centricity has long been at the heart of medical innovation, but today shapes its future. Achieving patient centricity at scale: a holistic and data-driven approach Clarivate Plc, a global leader in providing trusted…
Clarivate report: key branded drugs losing exclusivity in 2021
Posted 23 July 2021 Loss of exclusivity for innovators means opportunity for imitators. Clarivate Plc, a global leader in providing trusted information and insights to accelerate the pace of innovation, announced the launch of its new report identifying…
Clarivate report: nearly 70% vaccinated by September 2021
Posted 23 July 2021 Clarivate Forecasts Nearly 70% of North American, European and Asia Pacific Adult Populations Will Be Vaccinated for COVID-19 by September 2021 New report analyses how the emergence and increased availability of vaccines will impact…
Johnson & Johnson Innovation announces extension of partnering office at Monash University
Date Posted – 15 July 2021 Victorian State Government extends financing of JJIPO@Monash for an additional two years Extension will further boost Victorian hub for researchers and early-stage companies to connect with industry experts and deliver novel healthcare…
Ground-breaking discovery delivers hope for treating COVID-19
Posted 30 June 2021 Melbourne biosciences company and BioMelbourne member Esfam Biotech has announced it is on track to commence human trials for a COVID-19 treatment by the end of 2021. As Australians face the reality of more…
Super-charging the immune system to fight cancer!
Posted 28 June 2021 Cartherics and ToolGen announced today that they have entered into a commercial licence agreement. Under the agreement, Cartherics obtains world-wide rights to ToolGen’s intellectual property relating to the use of CRISPR/Cas9 for genome editing…
BioMelbourne Network’s Merchandise Store
BioMelbourne Network’s online merchandise store is now open! Click here to purchase official BioMelbourne Network: T-Shirts & Polos Hoodies & Jackets Hats Bags & Accessories Get 5% off on your first order by entering discount code LAUNCH at…
Investors buoyed by positive data for Immutep’s immunotherapy
Date Posted – 7 June 2021 Small cap immunotherapy biotech Immutep is a step closer to commercialising its leading drug candidate, “efti”, after releasing promising data showing the effectiveness of the drug in treating various types of lung,…
